Age-related macular degeneration ͑AMD͒ is a leading cause for vision loss for people over the age of 65 in the United States and a major health problem worldwide. Research for new treatments of the wet form of the disease using kilovoltage stereotactic radiosurgery is currently underway at Oraya Therapeutics, Inc. In the present study, the authors extend their previous computational stylized model of a single treated eye ͓Med. Phys. 35, 5151-5160 ͑2008͔͒ to include full NURBSbased reference head phantoms of the adult male and female using anatomical data from ICRP Publication 89. The treatment was subsequently modeled in MCNPX 2.5 using a 1 ϫ 1 ϫ 1 mm 3 voxelized version of the NURBS models. These models incorporated several organs of interest including the brain, thyroid, salivary glands, cranium, mandible, and cervical vertebrae. A higher resolution eye section at 0.5ϫ 0.5ϫ 0.5 mm 3 voxel resolution was extracted from the head phantoms to model smaller eye structures including the macula target, cornea, lens, vitreous humor, sclera/retina layer, and optic nerve. Due to lack of literature data on optic nerve pathways, a CT imaging study was undertaken to quantify the anatomical position of the optic nerve. The average absorbed doses to the organs of interest were below generally accepted thresholds for radiation safety. The estimated effective dose was 0.28 mSv which is comparable to diagnostic procedures such as a head radiograph and a factor of 10 lower than a head CT scan.
I. INTRODUCTION
Age-related macular degeneration ͑AMD͒ is a leading cause of vision loss for people over the age of 65 in the United States and a major health problem worldwide.
1 Advanced AMD has dry and wet forms which lead to blurring or blackening of the central vision while peripheral vision is retained. 2, 3 The dry ͑atrophic͒ form occurs from atrophy of the retinal pigment epithelial layer below the retina, causing loss of rods and cones in the central portion of the eye. The wet ͑neovascular͒ form begins with the formation of fibrovascular tissue from the choroids through the Bruch membrane. 4 This choroidal neovascularization grows beneath the pigment epithelium or into the sensory retina. As a consequence, there is often leakage and bleeding from the vessels that will lead to increased tension at the macular lesion resulting in severe loss of vision and ultimately blindness if left untreated.
There are currently a number of treatments used to help slow down the process of the disease including photodynamic therapy ͑PDT͒ using verteporfin ͑Visudyne ®, Novartis, Basel, Switzerland͒ 5 and intraocular drug therapy with ranibizumab ͑Lucentis®, Genentech, San Francisco, CA͒ 6 or pegaptanib sodium ͑Macugen®, OSI-Eyetech, New York, NY͒. 7 Radiation therapies have also been applied as treatments for the wet form of AMD. 8 These treatments include both intraocular, epiretinal delivery of beta radiation 9, 10 and external radiations including proton therapy, Gamma Knife radiosurgery ͑GKS͒, and high-energy external beam radiotherapy.
sues using a stylized model of the eye based on dimensional data from the National Council on Radiation Protection and Measurement Report No. 130 ͑Ref. 20͒ for geometric input to the MCNPX code. The results of that study provided insight into beam characterizations for optimal therapy applications: ͑1͒ A 1 mm focal spot size, ͑2͒ a 100 kVp maximum tube potential, ͑3͒ a beam entry with polar angle of 30°to primary gaze, and ͑4͒ a beam entry with azimuthal angles of 150°, 180°, and 210°. In the present study, the dosimetry characterization of the kilovoltage stereotactic AMD radiosurgery has been enhanced in a number of areas. First, the model structure was changed from MCNP combinatorial geometry to that based upon nonuniform rational B-spline ͑NURBS͒ surfaces. In the process, both a reference adult male head model and a reference adult female head model were constructed consistent with the anatomical data of the International Commission on Radiological Protection's ͑ICRP͒ Publication 89. 21 Second, the anatomic model of the previous study has been expanded to include the entire head and neck of the patient to model critical nontargeted structures of the brain, cranial bone marrow, cranial endosteum, thyroid, and salivary glands. These additional tissues thus allow for the assessment of effective dose from this treatment so that comparisons of relative stochastic risk may be made against other medical imaging and therapy procedures. Third, a more critical evaluation of optic nerve orientation was undertaken based upon CT imagingbased measurements of optic nerve pathways as seen in a 20 male and 20 female representative patient population. Finally, refinements to the irradiation and macula targeting were incorporated to conform to prototype experiments currently underway at Oraya Therapeutics, Inc.
II. MATERIALS AND METHODS

II.A. Description of stereotactic radiosurgery for AMD
Based on the studies suggesting that radiosurgery may be a viable option for wet AMD treatment, a device ͑I-Ray™͒ has been developed by Oraya Therapeutics, Inc. ͑Newark, CA͒ that individually delivers three x-ray beams through the pars plana to overlap on the predicted foveal center location via a robotically controlled system. The photon beam is characterized by a divergent profile with a diameter of approximately 3.5 mm upon scleral entry and 4 mm at the retina. An absorbed dose of up to 24 Gy to the macula is delivered at 8 Gy per treatment beam. Three beams were chosen to disperse the scleral entry dose, the dose to the edge of the lens closest to each beam, and the dose to the orbital bone and brain tissue. The 100 kVp x-ray beams originate from an anode target with a 1 mm focal spot that is 15 cm from the macula target. The geometric axis of the eye is defined as the line that intersects the point on the distal portion of the cornea and is perpendicular to the corneal curvature at this point. The posterior pole is the point where the geometric axis intersects the retina. The beam geometries can be described using a spherical 3D polar coordinate system with the z axis aligned with the geometric axis but transposed by an offset described subsequently. For all three beam angles, the nominal polar angle is 30°; however, if the scleral entry point of the beam is less than 4 mm from the limbus during a given patient treatment, the I-Ray™ device will readjust that polar angle until the 4 mm criterion is met. The azimuthal angles are described in the coronal plane of the patient such that 0°i s superior to the patient and an angle of 90°would be toward the nose for a treatment of the right eye. The beam azimuthal entry angles chosen for current prototype therapies are 150°, 180°, and 210°͑i.e., 5, 6, and 7 o'clock positions͒. The treated eye of each patient is fitted with a suctionenabled contact lens with a central post and control-yoke housing three optically sensed fiducial markers ͑I-Guide™͒. Motion of the patient's eye is substantially reduced by the I-Guide and the residual motion is tracked in real time using a two-camera imaging system. Eye motion that would result in substantial dose outside the target area triggers an interruption of the x-ray beam. Targeting error due to patient motion is monitored and maintained below 400 m on the retina. As a result, no deviation from the primary gaze was assumed during treatment simulation in this study. However, as described further in Secs. II D and III B, our retrospective CT-based study of the optic nerve position inherently included variations in the gaze angle and resulting optic nerve position and radiation dose that are beyond those permitted clinically during ocular radiotherapy using the I-Ray™ system.
II.B. The macula and foveal offset
In ocular anatomy, the fovea is known to be offset from the posterior pole of the eye. An evaluation of this separation was performed in-house at Oraya Therapeutics, Inc., using a customized Canon CR-45 UAF nonmydriatic fundus camera with a low-power laser beacon and an anterior imaging system with added collinear at the imaging axis. When a subject's eye is oriented such that the reflection of the laser beacon and the center of the limbus boundary coincide with the system axis as seen in the anterior eye view, the laser beacon position in the fundus image occurs at the intersection of the geometric axis with the retina ͑i.e., the posterior pole͒.
Analysis of these fundus images from seven healthy volunteers showed that the nominal fovea is located 1.25 mm laterally and 0.50 mm inferiorly from the posterior pole. The current treatment involves aligning the system to the geometric axis of the eye, followed by a translation of the device by the offset in order to target the nominal fovea. A retinal geography of the foveal offset is shown in a representative fundus image in Fig. 1 . This offset is important not only for more accurate targeting of subfoveal disease but also because it moves the treatment beams away from the optic disc, substantially reducing the optic nerve dose. Allowance for foveal offset was not considered in our previous dose characterization study. 18 Further studies have confirmed the validity of the offset. A total of 48 additional eyes, both healthy and low vision, were analyzed for the position of the fovea relative to the posterior pole. 36 Similar results were obtained. Additionally, as part of a larger targeting study, 13 cadaver eyes were dissected and the position of the fovea was compared to the positions of needles placed through the retina at the point of treatment. The average position of the fovea was found to be within 100 m in the lateral-medial direction and 100 m in the superior-inferior direction of the nominal fovea as defined by the offset. 
II.C. Head model geometry
Development of a whole-body phantom was completed within the Advanced Laboratory for Radiation Dosimetry Studies ͑ALRADS͒ research group at the University of Florida. The phantom was created from ͑1͒ segmentation of patient CT images using 3D-DOCTOR™ ͑Able Software Corp., Lexington, MA͒ which allows the regions of interest in axial CT slices to be highlighted in the 3D reconstruction and ͑2͒ modification of the resulting model to match the ICRP Publication 89 reference dimensions following conversion to flexible NURBS surfaces using the software RHINOC-EROS™ ͑McNeel North America, Seattle, WA͒. The detailed methodology of the entire process has been given previously by the ALRADS research group. 22, 23 Following these general procedures, the skeleton, head contour, major organs, and tissues ͑salivary glands, extrathoracic airways, tongue, tonsils, brain, and pituitary gland͒ were segmented from the patient CT data. The segmented model was imported into RHINOCEROS™ for conversion to NURBS surfaces. The male and female NURBS models are shown in Fig. 2 . The left and right eyes have a reference total mass of 15 g and a reference total volume of 14.56 cm 3 . The left and right lenses have a reference total mass of 0.5 g and a reference volume of 0.42 cm 3 . ICRP Publication 89 only gives reference mass and density for the lens and total eye structure, so additional ocular detail was added based on dimensions given in NCRP Report No. 130. 20 However, the dimensions used in NCRP Report No. 130 are not fully compatible with the ICRP Publication 89 reference values, and thus the dimensions used to create this model were modified slightly to ensure consistency with ICRP 89. The NURBS eye model with dimensions is shown in Fig. 3 .
While the macula is a region within the retina in human anatomy, its small size does not permit direct segmentation within CT images, and thus it must be computationally modeled as a separate structure for dosimetry purposes. In this study, the macula was modeled as a cylinder 4 mm in diameter and 0.5 mm in thickness. The macula is placed within the posterior region of the eye and translated according to the foveal offset. The cylinder is also rotated slightly to correspond with the curvature of the eye in this region. Coronal and axial views of the foveal shift are depicted in Figs. 4͑a͒ and 4͑b͒, respectively. In the coronal view, the crosshairs depict where the geometric axis would intersect the posterior pole of the eye. As shown in this figure, the macula has been moved 1.25 mm laterally and 0.5 mm inferiorly so that the center of the macula aligns with the fovea. The center of the optic disc is located 3.3 mm from the geometric axis and 4.6 mm from the center of the fovea. The axial view highlights the necessity to rotate the macula to better align with the curvature of the eye. The addition of the optic disc can also be seen in Figs. 4͑a͒ and 4͑b͒ which is modeled as a cylinder protruding into the vitreous humor from the end of the optic nerve 1.6 mm in diameter and 0.5 mm in height. The ocular models so described were applied to both the reference male and female head phantoms.
II.D. CT scan analyses of optic nerve orientation
The anatomical location of the optic nerve is well known in a qualitative manner. Nevertheless, there have been limited or no data quantifying the 3D anatomic position of the optic nerve and its pathway as it exits the eye and travels toward the brain. The optic nerve can be seen in both CT and MRI images, yet the optic nerve is a difficult structure to image in any one image slice because of its shape, size, and course. 24 Due to the absence of measurement data, the exit angle of the optic nerve was varied arbitrarily in our previous computational study. 18 However, due to the proximity of the macula to the optic nerve and disc and the possibility of damage to these structures during radiosurgery treatment, an improved method to quantify the optic nerve position and pathway was sought in the present study.
With Institutional Review Board approval ͑IRB No. 481-2007, University of Florida͒, 41 CT scans ͑20 male and 21 female͒ were obtained from Shands Hospital at the University of Florida for analysis of the optic nerve. The requirements for eligible CT sets included ͑1͒ maxillofacial axial scans, ͑2͒ 1 mm slice resolution, ͑3͒ soft tissue contrast settings, and ͑4͒ patient age over 18 years. The CT images were analyzed using 3D-DOCTOR™ ͑Able Software Corp., Lexington, MA͒. Measurements from the data included ͑1͒ vertical tilt angle of the optic nerve as it leaves the posterior region of the eye ͑parameter M 1 with sign that is positive in the superior direction and negative in the inferior direction͒, ͑2͒ horizontal tilt angle of optic nerve ͑parameter M 2 with sign that is positive in the medial direction and negative in the lateral direction͒, ͑3͒ optic nerve length from posterior of the eye to the posterior region of the orbit ͑parameter M 3 ͒, ͑4͒ optic nerve thickness at the posterior region of the eye ͑pa-rameter M 4 ͒, and ͑5͒ optic nerve thickness as it passes through the orbit ͑parameter M 5 ͒. From these measurements, four reference optic nerve models were created based on the combination of the most extreme exit angles in the superiorinferior ͑M 1 ͒ and medial-lateral ͑M 2 ͒ directions. A fifth optic nerve model was created from the mean of both angular measurements.
M 1 was calculated using the trigonometric relation tan −1 ͑X / Y͒ where X is obtained by counting the number of CT slices between the scan that showed the inferior portion of the optic nerve exiting the posterior region of the eye and the scan that showed the inferior portion of the optic nerve as it exits the orbit, and Y is the compressed, 2D length of the optic nerve. Measurement M 3 was calculated using Pythagorean's theorem with X and Y given M 1 . In many cases, the optic nerve appeared to significantly change direction at some point in its pathway ͑i.e., the optic nerve displayed some degree of slack in its pathway at certain gaze angles͒. In such a case, the angle in M 1 was made to the inflection point rather than to the posterior of the orbit to accurately depict an exit angle. A representation of M 1 is shown in Fig. 5 . The inferior side of the optic nerve was chosen for measurements because a clearer distinction could be made at the optic nerve-eye ball junction as compared to its superior side.
Obtaining values of M 1 in such a manner yields results relative to the axial plane in which the patient's head was scanned. This introduces undesirable variability since each patient's head may be oriented differently on the scanning table. To correct for patient head tilt, all angles measured were normalized to the Frankfurt plane, defined as the axial plane intersecting both the inferior point of the boney orbit and the superior point of the ear canal. 25 A correction factor was measured by performing 3D reconstruction of the patient's skull using an interactive segmentation tool in 3D-DOCTOR™. The resulting polygon mesh file was exported to RHINOCEROS 4.0 to make an angular measurement between the Frankfurt and scanning planes.
II.E. Optic nerve modeling
Based on the measurements previously described, five NURBS optic nerve models for both sexes were created with the male set shown in Fig. 6 . The primary optic nerve was created from the means of the five measurements, while the other four were created from the combination of extreme exit angles in the inferior-superior direction ͑value of M 1 ͒ and the medial-lateral direction ͑value of M 2 ͒. The resulting values used in construction of the optic nerves were Ϫ24.4 to +15.5 in the inferior-superior direction and were +18.9 to +28.5 in the medial-lateral direction. The five optic nerve models are labeled in this study as mean, sup-med, sup-lat, inf-med, and inf-lat, referring to the combination of exit angles used for each. While creating these extreme cases for optic nerve exit angle, two control points were maintained within both the male and female head models: ͑1͒ The junction of the eye and optic nerve and ͑2͒ the point at the posterior region of the orbit where the optic nerve enters the cranium. With these two points fixed, another point was needed to measure the exit angle, and so a plane was placed posteriorly with respect to the eye and perpendicular to the geometric axis. This plane was located posteriorly at a distance equal to the mean of Y in Fig. 5 , which was 14.3 mm for males and 9.6 mm for females. 
II.F. The Monte Carlo radiation transport code MCNPX
MCNPX is a general purpose Monte Carlo radiation transport code that tracks a variety of radiation particles over broad energy ranges. Simulations of ocular radiotherapy for AMD were performed using the MCNPX version 2.5.0 developed at Los Alamos National Laboratory ͑LANL͒. 19 A total of 10 7 sampling photon histories were completed for each simulation, and the resulting statistical errors were found to be less than 2% for the optic disc and less than 1% for all other tissues.
The relevant x-ray emission spectrum was generated for a tungsten anode tube operated at 100 kVp with anode angle of 12°and total filtration of 0.75 mm Al and 0.8 mm Be using the computer software described in Report No. 78 of the Institute of Physics and Engineering in Medicine. 26 Using the simulated x-ray energy spectrum, a divergent x-ray beam was modeled in MCNPX with a 1 ϫ 1 mm 2 area source representing a 1 mm 2 focal spot. The divergent beam was collimated by an explicit tungsten aperture to simulate a beam diameter of 4 mm at the macula target over a source-to-target distance of 150 mm. To avoid radiation dose to the lens and facial bones, a nominal polar angle of 30°from the geometric axis was adopted in this study. For the fixed polar angle, three different treatment azimuthal angles were selected: 150°, 180°, and 210°.
The head and eye models were voxelized for input to the MCNPX code. Each organ in the NURBS head model was tagged in RHINOCEROS 4.0™ and then exported. Using an in-house MATLAB code, VOXELIZER 5.0, the head model was voxelized to the desired resolution in a binary file. Using another in-house MATLAB code, the binary file was transformed to a lattice file, which can be read by MCNPX. The head model was voxelized to a resolution of 1 ϫ 1 ϫ 1 mm 3 ; however, the limiting size of the macula ͑0.5 mm in thickness͒ determines the resolution necessary for accurate voxelization. Consequently, a smaller sized and finer resolution eye section model was thus extracted from the full NURBS head model and voxelized at a 0.5ϫ 0.5 ϫ 0.5 mm 3 resolution. This eye section was carefully cropped to include the entire optic nerve and anterior portions of the brain for the treated right eye.
Absorbed doses to the brain, thyroid, salivary glands, bone marrow, and bone surfaces were calculated using the 1 ϫ 1 ϫ 1 mm 3 voxel head model, while doses to the macula, lens, optic disc, and optic nerve were calculated with the 0.5ϫ 0.5ϫ 0.5 mm 3 voxel eye model. The MCNP ‫ء‬ F6 tally was used to calculate to absorbed doses to the brain, thyroid, parotid gland, submaxillary gland, sublingual gland, macula, lens, optic disc, and optic nerve. To calculate dose to bone marrow and bone surfaces for the cranium, mandible, and cervical vertebrae, the F4 tally was used along with dose response functions described in ORNL/TM-8381/V1 
II.G. Calculation of effective dose
Once the MCNPX output for each organ tally was converted to absorbed dose per photon history, they were scaled by the number of histories necessary to deliver an absorbed dose of 8 Gy to the macula. This was done for both the male and female models at the 5, 6, and 7 o'clock beam angles. Effective dose was then calculated for a 3 ϫ 8 Gy treatment using steps described in ICRP Publication 103. 28 The parotid, submaxillary, and sublingual portions of the salivary glands were volume weighted to yield a single tissue dose for each target. The bone surfaces ͑endosteum͒ were weighted by fraction of bone surface across the entire skeleton. This tissue weighting was as follows: 15.3% cranium, 0.4% man- 29 The bone marrow dose was weighted by values given in Table IX .4 in ICRP Publication 89, 21 which reports the percentage of active marrow in each bone relative to total body active marrow as a function of age. The maximum age of 40 years was used here since the majority of patients undergoing AMD treatment are over the age of 65. Tissue absorbed doses ͑D T ͒ were reported in Gy for the brain, thyroid, salivary glands, active bone marrow, and bone surfaces for each treatment angle. Radiation weighting factors w R can be found in Table B .4. of ICRP Publication 103 ͑Ref. 28͒ and are 1.0 for photons. The equivalent doses for each organ were summed for each beam angle to give a total equivalent dose for a 3 ϫ 8 Gy treatment for both the reference adult male and female patients. These are sex averaged and were thus multiplied by tissue weighting factors w T for each organ yielding the overall effective dose E. Tissue weighting factors are found in Table B 
III. RESULTS AND DISCUSSION
III.A. Reference male and female head models
As noted above, two versions of the UF hybrid head phantoms exist-the NURBS phantom constructed from CT image segmentation and volumetrically adjusted to match individual reference tissue volumes and its voxelized counterpart. Table I gives the final tissue masses for both the hybrid-NURBS and hybrid-voxel adult male phantoms. Percentage differences from the ICRP 89 reference values are indicated along with the ICRP 89 targeted tissue mass and reference densities as given in ICRU Report 46. 30 Corresponding comparisons for the UF hybrid female head phantom are shown in Table II . Several tissues are not of dosimetric concern in this study but are shown for completeness. Masses for the esophagus and spinal cord are indicated as partial masses ͑i.e., fractional volume contained within the head phantoms͒. In general, targeted masses are achieved within 1%-2% of reference values for both sexes and both hybrid phantom types.
III.B. CT analysis of optic nerve measurements
Of the 41 subjects analyzed, only 40 were included in the analysis of optic nerve pathway. Female subject E was eliminated from the study as her head was oriented on the scanning table at an extreme angle in both the anterior-posterior and right-left directions. The mean and standard deviations for each measurement are given in Table III . The standard deviation was quite high for the vertical tilt ͑M 1 ͒, being 7.8°f or men and 8.4°for women. Consequently, it is useful to give the range for this measurement, which was from Ϫ17.6°T ABLE III. Mean and standard deviation for the five optic nerve measurements. ͑inferior tilt͒ to 15.5°͑superior tilt͒ for the male subjects and from Ϫ24.4°͑inferior tilt͒ to 9.7°͑superior tilt͒ for the female subjects. The medial-lateral tilt angle ͑M 2 ͒ for all subjects ranged from +18.9°to +28.5°. The angular measurements did not indicate any patterns that would suggest a difference between right and left optic nerves nor between males and females. However, the length measurements suggest that there are slight sex differences in optic nerve size. The standard deviations for these measurements were statistically stronger, being roughly 10% of the mean for each excluding that for the male values of M 4 , which was roughly 20%. Furthermore, the length measurements on the anterior portion of the optic nerve give some idea of where a dip normally occurs in the optic nerve slack ͑14.3 mm for men and 9.6 mm for women͒. The mean of the length measurements and the ranges of the angular measurements were used to provide representative optic nerve models. It is important to note that the gaze angle of the patient was not taken into account while taking these measurements, which is the main reason the standard deviations are larger than would be seen in a real patient population undergoing AMD radiotherapy ͑where the gaze angle is fixed via the I-Guide™ positioning device͒. While gaze angle can also be measured relative to the Frankfurt plane using a similar method to the optic nerve tilt angle measurement, it is difficult to develop a relationship between these two parameters. No attempt was made to rotate the eye into a primary gaze ͑or straight ahead͒ direction, as this would have an unknown effect on the anatomical position of the optic nerve.
III.C. Absorbed doses to nontarget tissues as a function of beam angles and sex
Mean absorbed doses to several nontargeted tissues are shown in Table IV for a 3ϫ 8 Gy treatment to the right eye.
The MCNPX output has been normalized by the number of photons necessary to deliver a dose of 8 Gy to the macula target. The lens received three-beam integral mean doses of 124 and 127 mGy in the reference male and female patients, respectively. The threshold for minimally detected changes or functional disability to the lens is 2000 mGy and the threshold for visual debilitation is 5500 mGy. 20 Despite the proximity of the optic disc to the macula target ͑4.6 mm͒, this tissue structure only receives a mean dose ranging from 200 to 239 mGy-a factor of 33-40 times less than that for the macula target. The average absorbed dose to the optic nerve, a critical part of this project, was found to increase with increasing beam azimuthal angle for the treated right eye. The optic nerve used for calculation in this section was that in the mean position. The highest optic nerve mean dose recorded was 112 mGy in the reference female patient at a 210°beam entry angle. The radiosensitivity of the optic nerve has been studied in patients whose optic nerve was unavoidably or unintentionally irradiated as a consequence of brain or head tumor radiotherapy. Optic nerve mean doses of 8000 mGy or higher might have some adverse consequences in some patients. 31 Other nontargeted tissue doses were also found to be insignificant. The highest dose to the optic nerve opposite treatment was 2.4 mGy for the female at a 210°beam entry. The mean absorbed doses to the brain ranged from 3.0 to 4.9 mGy per treatment beam. The mean absorbed doses to the thyroid and salivary glands were four to five orders of magnitude less, respectively, than that to the target for all beam angles and both sexes. Considering the mean absorbed doses to the bone structures in the head, the cranium received the highest dose to both the active marrow and endosteal tissues, but these doses were on the order of 9 mGy or less.
III.D. Dose volume histogram analysis
Dose volume histograms for the male and female mean optic nerve model are shown in Figs. 7͑a͒ and 7͑b͒ for a cumulative 3 ϫ 8 Gy treatment. These histograms display how the absorbed dose is distributed throughout the structure of the macula, lens, brain, and optic nerve. As shown, the absorbed dose to the macula is not quite evenly distributed, and the plots are thus designed to show a treatment with a maximum dose of 24 Gy to the target. For both sexes, a steep drop is observed for the lens, indicating that there are no hotspots. The brain DVH also drops off steeply, but small hotspots in the anterior portions of the brain ͑Ͻ10%͒ contribute doses ranging up to about 2.5 Gy. Nevertheless, for females only about 5% of the brain volume receives a dose exceeding 2.5 Gy and 95% of the male brain receives a dose less than 2 Gy.
The DVH of the mean male optic nerve shows that 2%-3% of that structure receives a dose exceeding 2 Gy, and that approximately 1% receives a dose exceeding 5 Gy. Less than 1% of the optic nerve volume receives a dose over 10 Gy with a maximum of about 12 Gy. The DVH of the mean female optic nerve shows that 2%-3% of the tissue volume receives more than 1 Gy with less than 1% receiving a maxi- mum dose of 8 Gy. It is important to note here that the threshold for adverse consequences given previously are for the average absorbed dose to the entire optic nerve, and that point doses higher than the threshold should not contribute to visual loss. The difference in DVHs for the male and female optic nerves indicates that the maximum dose is a function of optic nerve diameter at the posterior of the eye ͑value of M 4 ͒ since the mean of this measurement is 0.7 mm less for females.
The DVH plots for the sup-lat optic nerve are shown in Figs. 7͑c͒ and 7͑d͒. An optic nerve oriented in such a position is likely to come close to the beams exiting the eye, and patients in this case may receive localized optic nerve doses as high as 17.5 Gy for males and 15 Gy for females to less than 1% of its volume. Nevertheless, only 2%-3% of the male and ϳ1% of the female sup-lat optic nerve model receives a dose exceeding 8 Gy. This extreme situation for the reference male patient is shown in the form of a dose contour map in Fig. 8 . As shown, only the outermost periphery of the optic nerve is irradiated in this worst-case optic nerve position. Even still, the risk of radiation optic neuropathy ͑RON͒ is hypothesized to be exceedingly small as the vascular endothelium of the retinal arteries and veins-tissues at radiation risk for RON ͑Refs. 32 and 33͒-is found only within the central core of the optic nerve.
III.E. Patient effective dose
The relevant absorbed tissue doses necessary to calculate effective dose were weighted appropriately and are listed in Table V for the reference male and female head models. The calculation, based on the ICRP Publication 103 recommendations, yield an effective dose of 0.28 mSv for a 3 ϫ 8 Gy treatment to the macula. While the stereotactic AMD radiosurgery is therapeutic in nature, this value of effective dose compares very favorably with radiographic imaging doses including skull radiographs ͑0.1 mSv͒ and cervical spine radiographs ͑0.2 mSv͒, yet are much lower than seen in CT scans of the head ͑2 mSv͒ or neck ͑3 mSv͒. 34 In contrast, estimates of effective dose in megavoltage radiotherapy are significantly higher as in treatments of head and neck tumors ͑1870 mSv͒, brain metastases ͑270 mSv͒, and brain primary tumors ͑580 mSv͒. 35 Clinical trials are still underway and a smaller dose may eventually be prescribed. For example, if a 16 Gy total dose to the macula is shown to yield good clinical outcome, the estimated effective dose would be proportionally lower ͑e.g., 0.19 mSv͒.
IV. CONCLUSIONS
A new treatment for wet AMD involving kilovoltage stereotactic radiosurgery is proposed by Oraya Therapeutics, Inc. A three-beam treatment was evaluated in this study using NURBS-based reference head models of the adult male and adult female. Based upon anatomical variations in optic nerve pathways seen on patient CT images, five reference optic nerve models were evaluated in each head phantom. With the goal of delivering a total absorbed dose of 24 Gy to the macula target, mean absorbed doses and dose volume histograms were assessed for macula target and three nontargeted tissues: Lens, optic nerve, and brain. Mean absorbed doses to the lens were found to be 124 mGy in the reference male and 127 mGy in the reference female for the threebeam treatment. Integral mean absorbed doses to the optic nerve were 200 and 237 mGy in the reference male and female, respectively. Mean absorbed doses to the brain were shown to be 10.9 mGy for the male and 13.6 mGy for the female patient phantom. It is noted that in the CT analysis, variations about the clinically relevant primary gaze angle were realized, and thus the optic nerve models created in this study are considered to be extreme realizations in treated patients. Mean absorbed doses to other nontargeted tissues of the head were assessed as well including bone marrow, skeletal endosteum, salivary glands, thyroid, and brain. These doses were assessed in both the reference male and female head phantoms from which the effective dose could be estimated as per the ICRP Publication 103 schema. The effective dose for the proposed stereotactic AMD radiotherapy is estimated to be 0.28 mSv which is a factor of ϳ10 2 -10 3 lower than seen in external beam radiotherapy, a factor of ϳ10 lower than seen in head CT imaging, and is comparable to that seen in radiographic imaging of the head and neck.
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